Atezolizumab (Tecentriq®) in combination with carboplatin and etoposide is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
|NCPE Assessment Process||Ongoing|
|Rapid Review commissioned:||19/08/2019|
|Rapid Review completed||16/09/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care.|